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The antifungal agent flucytosine was found to be active in vitro against Aspergillus fumigatus isolates when
the MIC was determined at pH 5.0 instead of pH 7.0. The in vitro MIC at pH 5.0 corresponded to the in vivo
efficacy of flucytosine monotherapy in a murine model of invasive aspergillosis.
The efficacy of flucytosine for the treatment of invasive
aspergillosis (IA) has been controversial, although the evi-
dence supporting its use for this condition is limited (5, 10,
11). Most guidelines do not recommend the use of the drug
for the treatment of IA (1, 13), although use of the combi-
nation of amphotericin B and flucytosine for the treatment
of Aspergillus osteomyelitis and joint infection was recom-
mended previously (5).
Most isolates of Aspergillus species are not susceptible to
flucytosine, with MICs typically being 64 mg/liter (8). How-
ever, we previously demonstrated that the activity of flucy-
tosine against Aspergillus species increased when the pH of the
medium was lowered from 7.0 to 5.0 (8). Viviani et al. (12)
showed that the in vitro activity of flucytosine against Crypto-
coccus neoformans at pH 5.4 correlated well with the clinical
outcome. We investigated the flucytosine MIC distribution of
Aspergillus fumigatus at pH 7.0 and pH 5.0 and determined
which condition of MIC testing best corresponded with in vivo
efficacy in a nonneutropenic murine model of IA.
The in vitro activity of flucytosine against 50 clinical A.
fumigatus isolates from our private fungus culture collection
was determined by using the microdilution format of the CLSI
(formerly the NCCLS) M38-A protocol (6). The isolates were
cultured from clinical specimens from patients admitted to the
Radboud University Medical Center and other Dutch hospitals
between 1999 and 2005. All isolates were tested in duplicate at
pH 7.0 and pH 5.0, and the MIC was read as the 50% inhibi-
tion of growth compared to the growth for the control. The pH
was adjusted to 5.0 by using 100 mM citrate buffer.
Female CD-1 outbred mice (weight, 20 to 29 g; Charles
River Laboratories, Sulzfeld, Germany) were used. The animal
studies were conducted in accordance with the recommenda-
tions of the European Community (Directive 86/609/EEC, 24
November 1986) and were approved by the institutional animal
care and use committee of Radboud University. Inocula were
prepared as conidial suspensions in saline containing 0.05%
Tween 80, counted microscopically, and adjusted to the re-
quired concentration. Mice were infected with the 90% lethal
dose (LD90) by injection of 0.1 ml of the conidial suspension
into the orbital vein.
Flucytosine was dissolved in distilled water, according to the
instructions of the manufacturer, and administered intraperi-
toneally. Treatment was begun 2 h after infection. Groups of
10 mice each were treated for 7 days with 100 mg/kg of body
weight every 6 h (q6h), 100 mg/kg every 12 h (q12h), 200 mg/kg
q6h, and 200 mg/kg q12h. Control mice were infected but
received only distilled water. Animals were checked twice daily
for clinical signs and mortality. Mortality was recorded every
day for up to 8 days after the end of treatment. Statistical
analyses were performed with the GraphPad Prism (version
4.00) program (GraphPad Software, San Diego, CA). Statisti-
cal significance was defined as a P value of 0.05.
The median MIC at pH 7.0 was 128 mg/liter (range, 16 to
1,024 mg/liter), whereas at pH 5.0 it was 0.125 mg/liter (range,
0.063 to 512 mg/liter). The geometric mean decrease in the
MIC was 9.69 twofold dilution steps (Fig. 1). Only two isolates
showed a less significant decrease. One of these (isolate AZN
58, which was flucytosine resistant) was selected to determine
the in vivo efficacy of flucytosine monotherapy. The MIC of
this isolate at pH 5.0 was 512 mg/liter (Fig. 1). The efficacy of
flucytosine against this isolate was compared with that against
an isolate (isolate AZN 8196, which was flucytosine suscepti-
ble) that was previously shown to respond to flucytosine mono-
therapy (9). This isolate showed a decrease in the MIC from
512 mg/liter at pH 7.0 to 0.125 mg/liter at pH 5.0.
The LD90s were 1  10
7 CFU/mouse for both A. fumigatus
isolates, and the survival curves demonstrated that both A.
fumigatus isolates caused lethal infections in control mice (Fig.
2). The median survival time of the control mice infected with
the flucytosine-resistant A. fumigatus isolate (3.5 days) did not
differ significantly from that of control mice infected with the
flucytosine-susceptible isolate (4.5 days) (P  0.33). Figure 2A
shows the survival results for mice infected with the flucy-
tosine-resistant A. fumigatus isolate. Treatment with different
regimens of flucytosine did not significantly prolong the sur-
vival of the treated mice compared to that of the control mice
(P  0.33). Figure 2B shows the survival results for mice
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infected with the flucytosine-susceptible isolate. Treatment
with flucytosine at 100 mg/kg q6h, 200 mg/kg q6h, and 200
mg/kg q12h significantly prolonged the survival of the treated
mice compared to that of the control mice (P  0.01), while
treatment with flucytosine at 100 mg/kg q12h did not (P 
0.19).
The in vivo outcome of flucytosine monotherapy against the
two A. fumigatus isolates correlated well with the in vitro sus-
ceptibilities obtained with RPMI 1640 medium at pH 5.0. Al-
though the CLSI method has improved the intra- and inter-
laboratory agreements, the correlation between the results
obtained by this method and the clinical outcome has not been
clearly established for some antifungal agents. In this study, we
showed that the in vitro results for flucytosine against A. fu-
migatus obtained by the CLSI method correlated with the in
vivo outcome only when the pH of the medium was 5.0, similar
to the observations reported from studies with C. neoformans
(12). The results show that efficacy to nearly maximum survival
can be obtained with the highest daily dose of flucytosine used
(800 mg/kg) if the strain is susceptible. Because the half-life of
about 0.5 h in mice is shorter than the one of 2.5 to 5 h in
humans, the exposure during this dosing regimen is compa-
rable to that in humans during a regimen of 150 mg/kg/day
(1, 9, 13).
Flucytosine is taken up by fungal cells by the enzyme cyto-
sine permease (7). This carrier system is an active process
which occurs via H symport, which is required for proton
expulsion (4). Once it is inside the fungal cell, flucytosine is
rapidly deaminated to 5-fluorouracil by means of the enzyme
cytosine deaminase (10). In Saccharomyces cerevisiae, the base-
transport activity parameters (Km and Vmax) are dependent on
the concentration of the cosubstrate H (3). Furthermore, an
increase in the extracellular proton concentration (i.e., a de-
crease in the pH) resulted in a decrease in the Km values for
adenine, hypoxanthine, and cytosine uptake and a maximum
Vmax value at about pH 5.0 (2). This could explain the in-
creased activity of flucytosine against A. fumigatus at pH 5.0,
due to the increased uptake of the drug. In IA, the pH at the
site of infection might be less than 7.4 due to the metabolism
of glucose by Aspergillus and the subsequent formation of or-
ganic acids, as suggested before (9).
This study provides evidence that the majority of clinical A.
fumigatus isolates are susceptible to flucytosine at pH 5.0 and
that for two isolates the MIC at this pH corresponded to in
vivo efficacy, but this was not the case for the MICs determined
at pH 7.0. Flucytosine could potentially be of clinical benefit
for the treatment of abscesses in the brain or bones. Given the
increased interest in combination therapy for IA, it might be
appropriate to investigate flucytosine further in preclinical
studies.
Part of this study was supported by an unrestricted grant from
Valeant Pharmaceuticals.
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